Introduction
Programmes of immunisation against rubella are designed to prevent the consequences of infection at a particular point in a woman's life-during early pregnancy. Thus while immunity in, say, over 80% of the population may be acceptable for some conditions, success with rubella depends on achieving, in women, immune rates close to 100% in advance of the childbearing years. In contrast with, say, the United States, British policy is directed only at girls and at achieving individual immunity through vaccination. Hence general practitioners are anxious to ensure that all young women on their lists are immune to rubella before their first pregnancy. The general practitioner, however, cannot identify from his records those who have had natural infection from those who have not, those who were vaccinated from those who were not, and those who were vaccinated and failed to seroconvert. At present, therefore, he identifies the immune state of all pregnant women attending his antenatal clinic and vaccinates those who are seronegative in the early postpartum period. But he must also investigate and counsel those women who might have rubella or be in contact with rubella infection in early pregnancy.
In Glasgow a rubella immunisation programme began in March 1971, when all 13-year-old girls were offered vaccination. The names of those vaccinated are notified to the appropriate general practitioner. The proportion of girls vaccinated varied little during 1975-8, the overall proportion being 86 6% (table I) . Cendevax was used until 1977 and Almevax, said to give more lasting immunity, used thereafter. From 1977 the policy was to offer vaccination to all girls in their first year at secondary school. participates only in giving, say, 85 vaccine doses for every 100 girls offered vaccination, with a major part of the checking of immune state delayed to the stage of the antenatal clinic. The comparison does not include the repetition of tests which may occur between general practitioners and hospitals. In our proposed strategy activities of the antenatal clinic would be transferred to the school, which would increase the cost of the School Health Service but greatly reduce the cost in the antenatal sector. These cost savings would be substantial. Table IV compares the cost of the present system (which for vaccine and serotests we estimate as £213-50 per 100 women) with that of our proposed strategy, which takes advantage of the benefit of natural immunity. The cost per 100 women by this approach is about £1 12 for the serotests and vaccine, a saving of some 480%.
The annual saving in a city such as Glasgow with a need to vaccinate 8500 girls a year would be about £9000. Similar arrangements apply to the need for blood grouping, which may even be repeated for the same person in each pregnancy. Blood taken for estimating rubella immunity could also be used to determine blood group, and there are clear benefits from women having an early knowledge of both blood group and rubella immunity. An extension of our proposal might be to provide a card for all schoolgirls on which to record their blood group, immune state, immunisation, and other relevant information. Probably such a card would be preserved and the information available later to those responsible for their care with a consequent improvement in patient care at no additional cost. Both infusion methods, however, require fairly expensive infusion pumps. An alternative method of providing continuous analgesia without the problems associated with infusion techniques might be to give, infrequently, a narcotic with a long half life, and low clearance -for example, methadone. We report that methadone produces prolonged postoperative analgesia after a single intravenous dose.
Patients, methods, and results
Methadone was administered as a 20 mg intravenous bolus (over one minute) when cardiovascular stability returned after induction of anaesthesia in 19 healthy adult patients undergoing elective surgery (anterior spinal fusion 10, cholecystectomy four, other abdominal surgery five). Blood was collected at appropriate time intervals for determination of methadone concentration and hence pharmacokinetics in the postoperative period. No narcotic was used for premedication, and methadone was the only narcotic used during the intraoperative period. A volatile anaesthetic agent (enflurane) was added if the depth of anaesthesia associated with the methadone, nitrous oxide, and relaxant was considered to be inadequate.
Supplementary analgesia in the postoperative period was given at the request of the patients, who had been informed preoperatively that they had the choice of intramuscular (narcotic) or oral (non-narcotic) analgesia when they thought it necessary. Blood was collected immediately before any postoperative analgesic medication was given to calculate the minimum effective analgesic blood methadone concentration and the duration of analgesia. The blood methadone concentration was measured by gas chromatography based on a previous method.3 Standard curves were reproducible and passed through the origin, and the limit of sensitivity of the assay was 5 ,ug/l. Dahlstrom et al.4 This figure was obtained for pain during operation (in children 7-15 years old), which would be expected to be higher than that necessary to control postoperative pain.
IlCalculated from blood:plasma ratio (X)-that is, plasma concentration -blood concentration/X.
Comment
The prolonged postoperative analgesia (median value 25 hours) obtained after a single intravenous dose of methadone is similar to the terminal half life (mean 35 hours). Furthermore, there appears to be a minimum effective analgesic concentration of methadone (median value 35 tcg/l). Previous studies1 have shown a similar relation for pethidine in the treatment of postoperative pain (mean value 460 ,Lg/l). Our results suggest that there may be a direct relation between minimum analgesic blood concentration and potency for the narcotic agonists studied (see table) .
Pharmacokinetic studies have shown that clearance of methadone is about one-fifth of that of either morphine or pethidine (0-6-0-8 1/min). The mean distribution half life was only eight minutes, indicating that the blood methadone concentration falls rapidly after bolus intravenous administration. The distribution phase should therefore be complete 45-60 minutes after administration. The
